Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2

Thanh-Truc Huynh, Karel Pacak, Frederieke M Brouwers, Mones S Abu-Asab, Robert A Worrell, MacClellan M Walther, Abdel G Elkahloun, David S Goldstein, Susannah Cleary and Graeme Eisenhofer

Abstract

Objective: Phaeochromocytomas in patients with multiple endocrine neoplasia type 2 (MEN 2) produce adrenaline, whereas those with von Hippel-Lindau (VHL) syndrome do not. This study assessed whether these distinctions relate to differences in expression of the transporters responsible for uptake and storage of catecholamines – the noradrenaline transporter and the vesicular monoamine transporters (VMAT 1 and VMAT 2).

Methods: Tumour tissue and plasma samples were obtained from 31 patients with hereditary phaeochromocytoma with VHL syndrome and 13 with MEN 2. We used quantitative PCR, Western blotting, electron microscopy, immunohistochemistry and measurements of plasma and tumour catecholamines to assess differences in expression of the transporters in noradrenaline-producing vs adrenaline-producing hereditary tumours. These differences were compared with those in a further group of 26 patients with non-syndromic phaeochromocytoma.

Results: Adrenaline-producing phaeochromocytomas in MEN 2 patients expressed more noradrenaline transporter mRNA and protein than noradrenaline-producing tumours in VHL patients. In contrast, there was greater expression of VMAT 1 in VHL than MEN 2 tumours, while expression of VMAT 2 did not differ significantly. These differences were associated with larger numbers of storage vesicles and higher tissue contents of catecholamines in MEN 2 than in VHL tumours. Differences in expression of the noradrenaline transporter were weaker, and those of VMAT 1 and VMAT 2 stronger, in noradrenaline and adrenaline-producing non-syndromic than in hereditary tumours.

Conclusions: The findings show that, in addition to differences in catecholamine biosynthesis, phaeochromocytomas in MEN 2 and VHL syndrome also differ in expression of the transporters responsible for uptake and vesicular storage of catecholamines.

Introduction

Phaeochromocytomas are rare endocrine tumours with diverse phenotypes and highly variable clinical presentations but with the common feature that they synthesize, store, release, and metabolize catecholamines. Mutations affecting 5 different genes are associated with a sizeable proportion of the tumours (1, 2).

Multiple endocrine neoplasia type 2 (MEN 2), caused by mutations of the RET protooncogene, and von Hippel-Lindau (VHL) syndrome, due to mutations of the VHL tumour suppressor gene, are two of the more well characterized familial syndromes associated with a predisposition to phaeochromocytoma. Phaeochromocytomas in these two conditions have distinctive patterns of gene expression, indicating different pathways of tumourigenesis and explaining different phenotypic features of the tumours (3). Phaeochromocytomas in MEN 2 express phenylethanolamine N-methyltransferase (PNMT), the enzyme that converts noradrenaline to adrenaline, whereas tumours in VHL syndrome do not express PNMT (4). As a consequence, synthesis of noradrenaline and adrenaline and metabolism to normetanephrine and metanephrine characterize the former tumours, whereas synthesis of noradrenaline and metabolism to normetanephrine characterize the latter (5). Phaeochromocytomas in
VHL syndrome and MEN 2 also differ in the characteristics of catecholamine release (4, 6), but whether there may be associated differences in catecholamine uptake and storage is not established.

Previous studies indicated differences in expression of the cell membrane noradrenaline transporter and vesicular monoamine transporters (VMAT 1 and VMAT 2) in noradrenaline-and adrenaline-producing chromaffin cells or neurons (7–9). On the basis of these observations, we hypothesized that the expression profiles of catecholamine transporters in noradrenaline-producing phaeochromocytomas in VHL patients would differ from those in adrenaline-producing tumours in MEN 2 patients. The present study characterized expression of catecholamine transporters in phaeochromocytomas in the two hereditary syndromes.

Materials and methods

Patients

The study included 31 patients with hereditary phaeochromocytoma, 13 with the tumour due to MEN 2 and 18 due to VHL syndrome (Table 1). An additional 26 patients with phaeochromocytoma, in whom there was no evidence of a hereditary syndrome, were also included for comparison purposes. The 57 patients were selected from a larger group of 275 patients with phaeochromocytoma, who were initially tested for the tumour using biochemical tests carried out at the National Institutes of Health (NIH) in the 10-year period between 1994 and 2004. Inclusion into the study groups here depended on availability of high quality samples of tumour tissue for analyses of gene and protein expression. Blood and tumour tissue samples were obtained under studies approved by an appropriate Institutional Review Board (IRB), with informed consent from patients.

The diagnosis of MEN 2 or VHL syndrome in the 31 patients with hereditary phaeochromocytoma was confirmed by identification of germline mutations of the RET protooncogene or the VHL tumour suppressor gene. Four of the 18 VHL patients were related, including two brothers in one family and a brother and a sister in another family.

Table 1 Patient data.

<table>
<thead>
<tr>
<th>Hereditary phaeochromocytoma</th>
<th>Non-syndromic phaeochromocytoma*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MEN 2</td>
</tr>
<tr>
<td>n</td>
<td>13</td>
</tr>
<tr>
<td>Gender (F/M)</td>
<td>9/4</td>
</tr>
<tr>
<td>Age (mean, range)</td>
<td>38 (17–75)</td>
</tr>
</tbody>
</table>

*Patients with non-syndromic phaeochromocytoma are divided into two subgroups with either a noradrenergic (noradrenaline predominant) or adrenergic (mixed adrenaline and noradrenaline) biochemical phenotype as described elsewhere (3, 10). †Significantly (P < 0.02) higher age than in VHL patients; §Significantly (P < 0.01) higher age than in MEN 2 patients.
glutaraldehyde for examination by electron microscopy or formalin-fixed for immunohistochemistry.

Samples of normal adrenal tissue for examination of transporter gene expression were procured from three patients undergoing surgery at the NIH for renal cell cancer (requiring removal of both the kidney and adjacent adrenal). Adrenals were transected into sections and small samples of medulla (5–20 mg) were dissected away from surrounding cortex over ice. Paraffin embedded sections of normal human adrenal tissue ($n = 4$) were also purchased from Biocompare Pty Ltd (San Francisco, CA, USA).

**Tissue and plasma catecholamines**

Tissue and plasma concentrations of catecholamines (noradrenaline, adrenaline and dopamine) were quantified by liquid chromatography with electrochemical detection (11). Samples of tumour tissue were weighed frozen and homogenized in 5 to 10 volumes of 0.4 M perchloric acid containing 0.5 mM EDTA. Homogenates were centrifuged and supernatants collected for catecholamine determinations. Plasma concentrations of metanephrines (normetanephrine and metanephrine) were determined using a different liquid chromatography procedure after extraction onto solid phase ion exchange columns (12).

**Tumour catecholamine release**

Release of catecholamines by tumours was examined based on our previous observations of positive linear relationships of tumour size and total tumour catecholamine content with plasma catecholamines (4, 10). Increases of plasma catecholamines above normal in patients with phaeochromocytoma were estimated using our published data on normal plasma concentrations of noradrenaline and adrenaline in a reference population of 285 individuals (13). Subtraction of the mean plasma concentration of noradrenaline (1.18 nmol/l) and adrenaline (0.10 nmol/l) in this reference population from the respective concentrations of noradrenaline and adrenaline in patients with phaeochromocytoma provided estimates of increases in plasma concentrations of catecholamines due to tumours. The combined increases of noradrenaline and adrenaline above normal (nmol/l) were then divided by either tumour masses (g) or total tumour catecholamine contents (mmol) to obtain estimates of tumour catecholamine release as respective functions of tumour size (nmol/l per g of tumour) and catecholamine content (nmol/l per mmol of tumour catecholamine).

Since accurate weights of tumours were difficult to obtain for resected masses containing significant adhering connective tissue, tumour mass was calculated from the more accurate recordings of tumour dimensions. Mean diameters of each tumour were calculated from the cubed roots of rectangular volumes, as described previously (10). Volumes of tumours ($V$) were estimated using the formula for the volume of a sphere, $V = \frac{4}{3} \pi r^3$, where $r$, the radius, was derived from estimated mean diameters. Total tumour catecholamine contents were estimated from the product of tissue catecholamine concentrations and tumour mass (estimated from tumour volume, assuming a specific gravity of 1.0).

**Quantitative PCR**

RNA was extracted from phaeochromocytoma tumour tissue after homogenization in TRIzol reagent (Invitrogen, Carlsbad, CA, USA) followed by RNAse Maxi kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s recommendations. Total RNA (2 $\mu$g) was reversibly transcribed to cDNA using random hexamers. Quantitative PCR (TaqMan PCR), using a 7000 Sequence Detector (Applied Biosystems, Foster City, CA, USA), was used for quantification of mRNA for VMAT 1, VMAT 2 and the noradrenaline transporter as described previously (14). The primers and TaqMan probes were designed from the human noradrenaline

### Table 2 Oligonucleotide primers and probes used in PCR.

<table>
<thead>
<tr>
<th>Primers</th>
<th>Oligonucleotide sequence</th>
<th>Positions</th>
</tr>
</thead>
<tbody>
<tr>
<td>VMAT 1</td>
<td>Forward 5'-TGA CAT GGA GTT CAA AGA AGT CAA C 417–442</td>
<td></td>
</tr>
<tr>
<td>VMAT 1</td>
<td>Reverse 5'-GAG AGG CGA GGG CAT GTG 493–475</td>
<td></td>
</tr>
<tr>
<td>VMAT 1</td>
<td>TaqMan (FAM)-CAC CTC GCC CAT GCC GGA AGT T-(TAMRA) 451–473</td>
<td></td>
</tr>
<tr>
<td>VMAT-2</td>
<td>Forward 5'-TTC ATC AGA CCG CCA CAC A 406–425</td>
<td></td>
</tr>
<tr>
<td>VMAT-2</td>
<td>Reverse 5'-ACT GGG ACA GTC GGA AGG AA 470–450</td>
<td></td>
</tr>
<tr>
<td>VMAT-2</td>
<td>TaqMan (FAM)-CAC ATG GTG ACC AAC GCG TCC G-(TAMRA) 426–448</td>
<td></td>
</tr>
<tr>
<td>Noradrenaline transporter</td>
<td>Forward 5'-GGA AGC CAT CGG AGT TTC CT 1510–1529</td>
<td></td>
</tr>
<tr>
<td>Noradrenaline transporter</td>
<td>Reverse 5'-GAA CTTCCA GCA CAG TCT CCA GTA 1618–1565</td>
<td></td>
</tr>
<tr>
<td>Noradrenaline transporter</td>
<td>TaqMan 5'(FAM)-CAG GTT CAG CAA CGA CAT CCA GCA 1546–1571</td>
<td></td>
</tr>
</tbody>
</table>

*The number indicated corresponding to residues within VMAT-1 (Genbank accession no NM003053), VMAT-2 (L23205) or noradrenaline transporter (NM001043) sequence.*
transporter, VMAT 1 and VMAT 2 gene sequences using the Primer Express program from Applied Biosystems (Table 2).

Beta-actin was used as a housekeeping gene (Human β-actin Pre-Developed TaqMan Assay Reagents, Applied Biosystems) to normalize quantification of noradrenaline transporter, VMAT 1 and VMAT 2 mRNA for differences in the amounts of total RNA added to each cDNA reaction. PCR amplifications of β-actin and the noradrenaline transporter, VMAT 1 or VMAT 2 were carried out in the same tubes. Reaction tubes contained 20 ng cDNA product as template, 1 μmol/l for each of the forward and reverse primers for the noradrenaline transporter, VMAT 1 or VMAT 2, and 1 μmol/l for TaqMan probes for the noradrenaline transporter, VMAT 1 or VMAT 2. Reaction tubes contained 20 ng cDNA product as template, 1 μmol/l for each of the forward and reverse primers for the noradrenaline transporter, VMAT 1 or VMAT 2, and 1 μmol/l for TaqMan probes for the noradrenaline transporter, VMAT 1 or VMAT 2. PCR involved 40 cycles at the following temperature parameters: 15 seconds at 95 °C, 1 min at 60 °C. Input RNA amounts were calculated manually using the comparative Ct method for the target genes and β-actin.

Western blots
Western blot analysis of the noradrenaline transporter utilized samples of phaeochromocytoma tissue embedded in OCT blocks, which were sectioned (8–18 microns, depending on tumour size) and immediately lysed in T-per tissue protein extraction reagent, containing 12 mM bicine, 150 mM sodium chloride (pH 7.6) (Pierce Biotechnology, Rockford, IL, USA), with a protease inhibitor cocktail tablet (Roche Applied Science, Indianapolis, IN, USA). Western blot analyses of VMAT 1 and VMAT 2 utilized samples of frozen phaeochromocytoma tissue (about 20 mg), which were homogenized in 10 mM potassium phosphate buffer, pH 6.8 containing 1 mM EDTA, 10 mM 3-(3-cholamidopropyl) dimethylammonio 1-propane sulphate (CHAPS), 1 μg/ml aprotinin, 10 μg/ml each of leupeptin and pepstatin, and 1 mg/ml of Pefablock (Roche Applied Science). All tissue homogenates were centrifuged for 10 min at 10 000 g (4 °C), with supernatants removed and stored at −80 °C.

Different Western blotting protocols were used for each of the three transporters (Table 3). Tissue proteins with reducing agent were separated by electrophoresis on polyacrylamide gels and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). Unoccupied protein binding sites were blocked by incubating the membranes in blocking buffers overnight at 4 °C. Membranes were then incubated with primary antibodies at optimized dilutions. Membranes were washed with Tris buffer saline (50 mM Tris, pH 7.4, 0.9% NaCl) containing 0.05% Tween-20 and incubated with secondary antibodies. Target protein bands were visualized using appropriate immunodetection systems.

Table 3 Western blotting protocols for transporters.

<table>
<thead>
<tr>
<th>NET</th>
<th>VMAT 1</th>
<th>VMAT 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total protein</td>
<td>10 μg</td>
<td>10 μg</td>
</tr>
<tr>
<td>Type of gel</td>
<td>8% Tris-Glycine gel</td>
<td>4–12% NuPAGE Bis-Tris gel</td>
</tr>
<tr>
<td>Blocking buffer</td>
<td>TBS-T and 5% normal donkey serum (Jackson Immuno, Westgrove, PA, USA)</td>
<td>TBS-T and 5% dry milk</td>
</tr>
<tr>
<td>Primary antibody</td>
<td>Rabbit anti-human NET polyclonal antibody (kind gift from Dr David Christie, University of Auckland, refs 13, 14), 1:250, 72 h at 4 °C</td>
<td>Goat anti-human VMAT 1 polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 1:2000, 1 h at RT</td>
</tr>
<tr>
<td>Secondary antibody</td>
<td>Alkaline phosphatase conjugated anti-rabbit IgG, 1:5000, 45 min at RT</td>
<td>Horseradish peroxidase conjugated anti-goat IgG, 1:20 000, 1 h at RT</td>
</tr>
<tr>
<td>Immunodetection system</td>
<td>CDP-Star chemiluminescent method (Applied Biosystems)</td>
<td>Chemiluminescent method and using NIH image 1.62 software to perform densitometry analyses</td>
</tr>
</tbody>
</table>

NET, noradrenaline transporter; RT, room temperature.
**Electron microscopy**

Tissue was double-fixed in PBS-buffered glutaraldehyde (2.5%) and osmium tetroxide (0.5%), dehydrated, and embedded into Spurr’s epoxy resin. Ultrathin sections (90 nm) were made and double-stained with uranyl acetate and lead citrate, and viewed in a Philips CM10 transmission electron microscope. Vesicular granules were counted blindly in 10 representative tumours from five patients with MEN 2 and five patients with VHL syndrome. Counting was carried out for each tumour on progressive numbers of cells, with the mean count per cell tallied, until a consistent constant mean count was obtained over a final successive series of five cells counted. Counting was done at low magnification where whole cells could be visualized. Therefore, no count was done on partial cells. Since empty vesicles could only be visualized at high magnification, counting was restricted to vesicles containing distinct cores.

**Immunohistochemistry**

Formalin fixed sections of normal human adrenals (n = 4) and phaeochromocytoma tumour samples from MEN 2 (n = 8) and VHL (n = 8) patients were deparaffinized and rehydrated by washing twice for 10 min with xylene, followed by 2 × 2 min washes in 100%, 95% and 70% (v/v) ethanol. After rinsing with distilled water and immersion in warmed citrate buffer (0.01 M, pH 6.0) for 5 min, samples underwent antigen retrieval by immersion in hot citrate buffer (58 °C), followed by heating at 50% power for 5 × 5 min in a 1000 W microwave oven. Sections were allowed to cool to room temperature before washing for 3 × 10 min in 0.1 M phosphate buffer (pH 7.4). Sections were then pre-incubated for 1 h in a blocking solution consisting of 0.1 M PBS containing 10 mM Tris phosphate buffered saline (TPBS), 0.3% Triton X-100, 0.1% (w/v) sodium azide and 10% normal donkey serum (Jackson Immuno, Westgrove, PA, USA). Primary antibodies for the noradrenaline transporter (affinity purified rabbit anti-noradrenaline transporter antibody; 1:100, 0.125 μg/ml), as characterized elsewhere (15, 16), and for tyrosine hydroxylase (mouse monoclonal anti-tyrosine hydroxylase, 1:500; Diasorin, Saluggia, Italy) were diluted in the blocking solution and slides were incubated for 24 to 48 h at 4 °C in a humidified chamber. Following incubation, slides were washed (3 × 10 min in TPBS) and then incubated for 4 h at room temperature with species-specific secondary antibodies (donkey anti-rabbit Cy3, 1:500; Jackson Immuno; donkey anti-mouse fluorescein isothiocyanate, 1:500). Slides were then washed 3 × 10 min in TPBS and mounted in ProLong Antifade (Molecular Probes, Eugene, OR, USA).

Sections were examined using a Zeiss LSM PASCAL 5 equipped with Ar/Kr 488–514, He/Ne 543 lasers, used to excite Cy-3, FITC. Multipass emissions were collected through the following filters: FITC, bandpass 505–530; Cy-3, bandpass 560–515; using a 63x NeoFluor objective lens, pinhole, detector gain, and laser power were adjusted accordingly to acquire approximately 5 μm thick sections with few saturated pixels. Images were acquired with LSM 5 Image Browser software (Zeiss, Thornwood, NY, USA). While overall contrast was adjusted, no other modifications were made.

**Statistical analysis**

Statistical methods, performed with Statview (SAS Institute, Inc., Cary, NC, USA), included Student’s t-test, the Mann–Whitney test, regression analysis, and for comparisons involving more than two groups, analysis of variance with Sheffe’s test as the post-hoc test of choice. Logarithmic transformations were carried out before parametric analyses to correct for non-normally distributed data, as described elsewhere (13). Non-parametric analyses using the Mann–Whitney test were performed as a second check of statistical significance for all comparisons involving two groups. P-values for such comparisons are presented as the minimal level of statistical significance achieved by either test. In the single case where statistical significance (defined as a P-value less than 0.05) was not reached by both tests, the difference in P-values between tests is noted in the text and the legend to the particular figure. Relationships between variables were analysed by regression analysis using both parametric and non-parametric analyses, the latter using Spearman’s rank correlation coefficient. Only relationships that were significant by both regression analyses are described, with correlation coefficients and significance levels presented as obtained using parametric analyses.

**Results**

**Tumour and plasma catecholamines**

Noradrenaline accounted for 98% of the total catecholamine contents in phaeochromocytomas from VHL patients, whereas in MEN 2 patients, noradrenaline accounted for only 53% and adrenaline 47% of total tumour catecholamine contents (Table 4). Combined tissue concentrations of noradrenaline and adrenaline in MEN 2 tumours (59.8 ± 11.4 μmol/g) were 4-fold higher (P < 0.001) than concentrations in VHL tumours (15.3 ± 2.7 μmol/g). This difference reflected effects of both 9.3-fold higher (P < 0.001) tissue concentrations of adrenaline and 2-fold higher (P < 0.04) tissue concentrations of noradrenaline in tumours from MEN 2 patients than in those from VHL patients. Consistent with the above pattern and previous observations that increases in plasma normetanephrine and metanephrine accurately reflect tumour contents of noradrenaline and adrenaline (10), plasma concentrations of metanephrine were 18-fold higher (P < 0.001) in...
MEN 2 patients than in VHL patients, while normetanephrine concentrations were 2.3-fold higher in MEN 2 patients than VHL patients, though the latter difference did not reach significance.

Plasma concentrations of adrenaline were 9-fold higher ($P < 0.001$) in MEN 2 patients than in VHL patients, whereas plasma concentrations of noradrenaline were not significantly different (Table 4). Although the combined sum of plasma concentrations of noradrenaline and adrenaline did not differ between patients with VHL syndrome and MEN 2 ($5.9 \pm 1.1$ versus $5.8 \pm 1.6$ nmol/l), significant differences in catecholamine release emerged when differences in tumour size and tumour catecholamine content were considered. When corrected for differences in tumour mass, increases in plasma catecholamines in VHL patients were 2.5-fold higher ($P < 0.002$) than in MEN 2 patients. When further corrected for differences in total tumour catecholamine content, increases in plasma catecholamines in VHL patients were 6.3-fold higher than in MEN 2 patients.

Similar differences to the above in predominantly noradrenaline-producing (noradrenergic) VHL tumours and adrenaline-producing (adrenergic) MEN 2 tumours were also observed in patients with noradrenergic and adrenergic non-syndromic phaeochromocytomas.

### Table 4

<table>
<thead>
<tr>
<th></th>
<th>VHL ($n = 18$)</th>
<th>MEN 2 ($n = 13$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean tumour diameter (cm)</td>
<td>2.6±0.2</td>
<td>4.3±0.6*</td>
</tr>
<tr>
<td>Tumour catecholamines</td>
<td>Noradrenaline (μmol/g)</td>
<td>15.0±2.7</td>
</tr>
<tr>
<td></td>
<td>Adrenaline (μmol/g)</td>
<td>0.3±0.1</td>
</tr>
<tr>
<td>Plasma catecholamines</td>
<td>Noradrenaline (nmol/l)</td>
<td>5.8±1.1</td>
</tr>
<tr>
<td></td>
<td>Adrenaline (nmol/l)</td>
<td>0.1±0.0</td>
</tr>
<tr>
<td>Plasma metanephrines</td>
<td>Normetanephrine (nmol/l)</td>
<td>2.4±0.4</td>
</tr>
<tr>
<td></td>
<td>Metanephrine (nmol/l)</td>
<td>0.2±0.0</td>
</tr>
<tr>
<td>Tumour catecholamine release (nmol/l per g tumour tissue)</td>
<td>0.79±0.24</td>
<td>0.32±0.18*</td>
</tr>
<tr>
<td></td>
<td>(nmol/l per mmol tumour catecholamine)</td>
<td>76±21</td>
</tr>
</tbody>
</table>

All values are means±S.E.M. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$.

### Table 5

<table>
<thead>
<tr>
<th></th>
<th>Noradrenergic ($n = 11$)</th>
<th>Adrenergic ($n = 15$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean tumour diameter (cm)</td>
<td>3.6±0.4</td>
<td>5.0±0.6</td>
</tr>
<tr>
<td>Tumour catecholamines</td>
<td>Noradrenaline (μmol/g)</td>
<td>11.5±4.5</td>
</tr>
<tr>
<td></td>
<td>Adrenaline (μmol/g)</td>
<td>0.1±0.0</td>
</tr>
<tr>
<td>Plasma catecholamines</td>
<td>Noradrenaline (nmol/l)</td>
<td>25.3±7.6</td>
</tr>
<tr>
<td></td>
<td>Adrenaline (nmol/l)</td>
<td>0.4±0.1</td>
</tr>
<tr>
<td>Plasma metanephrines</td>
<td>Normetanephrine (nmol/l)</td>
<td>10.8±2.9</td>
</tr>
<tr>
<td></td>
<td>Metanephrine (nmol/l)</td>
<td>0.6±0.2</td>
</tr>
<tr>
<td>Tumour catecholamine release (nmol/l per g tumour tissue)</td>
<td>1.48±0.49</td>
<td>0.32±0.08**</td>
</tr>
<tr>
<td></td>
<td>(nmol/l per mmol tumour catecholamine)</td>
<td>200±88</td>
</tr>
</tbody>
</table>

All values are means±S.E.M. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$. 

www.eje-online.org
In particular, combined tissue concentrations of noradrenaline and adrenaline in adrenergic non-syndromic tumours (32.1 ± 10.4 μmol/gm) were 2.8-fold higher \((P < 0.04)\) than in noradrenergic non-syndromic tumours (11.6 ± 4.5 μmol/g). Furthermore, increases in plasma catecholamines as a function of tumour mass were 4.6-fold higher \((P < 0.007)\) in patients with noradrenergic than adrenergic tumours. When further corrected for differences in total tumour catecholamine content, increases in plasma catecholamines in patients with noradrenergic non-syndromic tumours were 5.9-fold higher \((P < 0.02)\) than in patients with adrenergic tumours.

**Expression of the noradrenaline transporter**

Quantitative PCR indicated a 6-fold higher \((P < 0.002)\) amount of noradrenaline transporter mRNA in phaeochromocytoma tumour tissue from MEN 2 patients than from VHL patients (Fig. 1A). Consistent with this, Western blot analysis indicated consistently detectable noradrenaline transporter protein in phaeochromocytoma tissue from MEN 2 patients, compared with no or only faintly detectable noradrenaline transporter protein in tumours from VHL patients (Fig. 1B).

Expression of the noradrenaline transporter, measured by quantitative PCR, tended to be higher in non-syndromic adrenergic tumours \((520 ± 170 \text{ relative units}, n = 9)\) than noradrenergic tumours \((292 ± 170 \text{ relative units}, n = 8)\), but this difference did not reach statistical significance. Thus, in contrast to the large difference in noradrenaline transporter expression in hereditary phaeochromocytomas, any difference in tumours from patients with non-syndromic phaeochromocytoma was relatively modest.

Expression of the noradrenaline transporter in the three samples of normal adrenal medulla \((47 ± 8 \text{ relative units})\) was relatively low compared with expression in phaeochromocytomas.

**Expression of vesicular monoamine transporters**

In contrast to expression of the noradrenaline transporter, expression of VMAT 1 mRNA was 69% lower \((P < 0.007)\) in phaeochromocytomas from MEN 2
patients than from VHL patients (Fig. 2A). Similarly, expression of VMAT 1 protein was 62% lower in MEN 2 than VHL tumours (Fig. 2C), but this difference did not reach significance. Expression of VMAT 2 mRNA and protein also tended to be lower in MEN 2 than VHL tumours, but these differences also did not reach significance (Fig. 2B & D).

Following a similar but more dramatic pattern to the differences in hereditary noradrenergic and adrenergic tumours, levels of expression of VMAT 1 and VMAT 2 were lower in adrenergic than noradrenergic non-syndromic phaeochromocytomas (mean±S.E.M.). Levels of expression of mRNA were determined by quantitative PCR in phaeochromocytomas from 15 patients with adrenergic tumours and 11 patients with noradrenergic tumours. Expression of VMAT 1 and VMAT 2 mRNA is shown relative to that of β-actin mRNA, as described in the Methods section. Expression of VMAT 1 and VMAT 2 protein in Western blots was determined by densitometry using NIH image 1.62 software in phaeochromocytomas from 13 patients with adrenergic tumours and eight patients with noradrenergic tumours. *Significantly (P < 0.05) higher expression in non-syndromic noradrenergic than adrenergic tumours. **Significantly (P < 0.001) higher expression in non-syndromic noradrenergic than adrenergic tumours. Note: The difference in VMAT 1 protein expression, although significant by parametric analysis (P = 0.038), failed to reach significance by non-parametric analysis (P = 0.070).

Expression of VMAT 1 mRNA in the three samples of normal human adrenal medulla (63±38 relative units) was intermediate between levels of expression in noradrenergic and adrenergic hereditary or non-syndromic phaeochromocytomas. Expression of VMAT 2 mRNA in the three samples (186±107 relative units) was similar to that in hereditary and non-syndromic adrenergic tumours, but lower than in non-syndromic noradrenergic tumours. There were significant positive relationships between expression of VMAT 1 mRNA and protein (r = 0.41,
\[ P = 0.006 \), VMAT 2 mRNA and protein \( (r = 0.30, P = 0.047) \), VMAT 1 and VMAT 2 mRNA \( (r = 0.68, P < 0.0001) \) and VMAT 1 and VMAT 2 protein \( (r = 0.64, P < 0.001) \) for the combined data from all four groups of phaeochromocytomas. Significant positive relationships were also found between expression of mRNA for VMAT 1 \( (r = 0.45, P = 0.002) \) or VMAT 2 \( (r = 0.54, P < 0.001) \) and increases in plasma catecholamines as a function of tumour size (Fig. 4). Relationships with increases in plasma catecholamines as a function of total tumour catecholamine contents were weaker, but also positively related to expression of mRNA for VMAT 1 \( (r = 0.35, P = 0.019) \) and VMAT 2 \( (r = 0.48, P < 0.001) \).

**Electron microscopy**

Electron microscopy revealed different ultrastructural morphologies of phaeochromocytoma tumour cells from VHL and MEN 2 patients (Fig. 5). MEN 2 tumour cells were filled with both noradrenaline and adrenaline granules, whereas VHL tumour cells contained fewer predominantly noradrenaline granules and many empty vesicles. Empty vesicles were not restricted to the regional vicinity of the cell membrane, but were scattered throughout the cytoplasm as a characteristic of VHL tumour cells. Empty vesicles were not observed in MEN 2 tumours. Numbers of catecholamine containing vesicles (vesicles with cores)
were 79% lower ($P = 0.012$) in VHL tumours than in MEN 2 tumours.

**Immunohistochemistry**

Immunohistochemistry indicated expression of the noradrenaline transporter in normal human adrenal medulla and phaeochromocytomas from patients with MEN 2 (D–F) and VHL syndrome (G–I). Staining of the transporter in the normal adrenal was present within the cytoplasm, and colocalized with staining for TH (C). In contrast, the pattern of staining for the noradrenaline transporter in tumour samples of both MEN2 and VHL patients was highly variable, and did not always appear to colocalize with TH. Thick arrows indicate granular staining for the noradrenaline transporter, thin arrows indicate red blood cells.

**Discussion**

This study extends previous observations about differences in catecholamine biosynthetic enzymes among hereditary forms of phaeochromocytoma to other key determinants of catecholamine system function — the transporters responsible for inactivation and storage of catecholamines via cellular uptake and vesicular translocation.

Phaeochromocytomas in the setting of MEN 2, which synthesize substantial amounts of adrenaline, expressed more of the noradrenaline transporter than did tumours in the setting of VHL, which produce negligible adrenaline. In contrast, phaeochromocytomas in VHL patients expressed more VMAT 1 than did those in MEN 2 patients. This was despite lower tissue catecholamine concentrations and numbers of catecholamine-containing secretory granules in tumours from VHL than from MEN 2 patients. Similar patterns to the above were observed in predominantly noradrenaline-producing (noradrenergic) vs adrenaline-producing (adrenergic) tumours in patients with non-syndromic phaeochromocytoma. However, differences in expression of the noradrenaline transporter were less pronounced, while differences in expression of VMAT 1 and VMAT 2 were more pronounced in non-syndromic than hereditary noradrenergic and adrenergic tumours.

The finding of greater noradrenaline transporter expression in adrenergic MEN 2 tumours than in noradrenergic VHL tumours agrees with other observations that expression of the noradrenaline transporter in rat adrenal chromaffin cells is confined to those cells that express PNMT, the enzyme that converts noradrenaline to adrenaline (9). Together, these findings are also consistent with those of Kobayashi and colleagues (17), who injected mice with tritium-labelled catecholamines and using autoradiography found larger amounts of radioactivity in adrenaline-containing compared with noradrenaline-containing adrenal medullary chromaffin cells. Similarly, the finding of higher expression of VMAT 2 in non-syndromic noradrenergic than adrenergic tumours, is consistent with other findings that VMAT 2 is expressed in noradrenaline-containing, but not adrenaline-containing chromaffin granules of bovine adrenal medulla (7). There are marked species variations in proportions of adrenaline and noradrenaline containing chromaffin cells (18). In the human adrenal medulla, virtually all chromaffin cells express PNMT. It is therefore unclear how findings of different populations of noradrenaline and adrenaline cells in various animal species relate to development of different catecholamine-producing phaeochromocytomas in humans. Possibly there may exist in the human adrenal medulla a small proportion of noradrenaline cells from which distinctly noradrenaline-producing tumours in VHL patients develop. Alternatively as suggested elsewhere (19), predominant production of noradrenaline in phaeochromocytomas may reflect dedifferentiation, with loss of expression of PNMT and other aspects of the adrenaline phenotype, such as the noradrenaline transporter, occurring more profoundly in hereditary than in sporadic tumours.
Since the noradrenaline transporter mediates the cellular uptake of radioiodinated metaiodobenzylguanidine (MIBG) (20), greater noradrenaline transporter expression in phaeochromocytomas from MEN 2 than VHL patients might be expected to make the imaging agent more suitable for localization of tumours in the former than in the latter syndrome. However, tumour visualisation with MIBG also depends importantly on translocation of the agent into catecholamine storage granules (21). Inhibition of VMAT 1 and VMAT 2, the transporters responsible for translocation of catecholamines into vesicles, reduces uptake and retention of MIBG by neuroendocrine tumour cells more consistently than does inhibition of the noradrenaline transporter (22). Thus, the greater expression of VMAT 1 in VHL compared with MEN 2 tumours and of both VMAT 1 and VMAT 2 in non-syndromic noradrenergic than adrenergic tumours might be expected to facilitate chromaffin cells and tumour cells in patients with non-syndromic phaeochromocytoma (9, 15, 23, 24). Regulated trafficking of the noradrenaline transporter from the cytoplasm to the cell surface appears to be an important mechanism regulating transporter function (25). Improved tumour visualisation and targeted radiotherapy of malignancies with MIBG by procedures designed to increase expression of the transporter (26, 27) may therefore benefit by additional consideration of the mechanisms regulating functional expression of the transporter at the cell surface.

Greater expression of VMAT 1 in tumours from VHL patients than from MEN 2 patients was associated with lower tumour tissue contents of catecholamines, lower numbers of catecholamine-containing chromaffin granules, and higher numbers of empty vesicles. These differences might reflect the more active release of catecholamines in predominantly noradrenergic than adrenergine-producing tumours observed elsewhere (4, 10), and verified here by the larger increases in plasma catecholamines as functions of tumour size and catecholamine content in noradrenergic than adrenergic hereditary and non-syndromic phaeochromocytomas. Increased expression of VMAT 1 in VHL compared with MEN 2 tumours and of both VMAT 1 and VMAT 2 in non-syndromic noradrenergic than adrenergic tumours might be expected to facilitate...
refilling of the depleted storage granules, a compensatory response to the more rapid turnover of catecholamine stores in predominantly noradrenaline- than adrenaline-producing tumours. This possibility is supported here by the findings of positive relationships between indices of tumour catecholamine release and expression of VMAT 1 and VMAT 2.

The diagram in Fig. 7 summarizes five differences in catecholamine system function in pheochromocytomas from MEN 2 and in VHL patients: (1) MEN 2 tumours produce adrenaline, whereas VHL tumours do not; (2) VHL tumours have lower numbers of catecholamine-containing vesicles and smaller tissue catecholamine stores than MEN 2 tumours; (3) VHL tumours release more catecholamines than MEN 2 tumours; (4) VHL tumours have less noradrenaline transporter expression; and (5) VHL tumours express more VMAT 1 than MEN 2 tumours.

In conclusion, the divergent expression profiles of catecholamine transporters in pheochromocytomas from MEN 2 and VHL patients provide further evidence of distinct genotypic differences contributing to the distinctive clinical catecholaminergic phenotypes in these two hereditary pheochromocytoma syndromes.

Acknowledgements

We gratefully acknowledge the gift of rabbit antibody to the noradrenaline transporter from Drs David L Christie (Auckland University, New Zealand) and Jacqueline Phillips (Murdoch University, Perth, Western Australia). We also thank Dr Massimo Mannelli (University of Florence, Florence, Italy) for assistance with patients and data collection. This research was supported by the Intramural Research Program on NIM, National Institute of Neurological Disorders and Stroke, National Cancer Institute, National Institute of Child Health and Human Development and National Human Genome Research Institute.

References


20 Glowniak JV, Kilty JE, Amara SG, Hoffman BJ & Turner FE. Evaluation of metiodobenzylguanidine uptake by the noradrenergic,


Received 29 April 2005
Accepted 21 June 2005